US
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Scientific Poster
Comprehensive 2D/3D RAS cell panel for mutation-specific inhibitor profiling: from screening to mechanistic validation
Targeting drug profiling using cancer cell line panels is a powerful approach for evaluating efficacy, selectivity, and mechanism of action of emerging therapeutics.
Our preclinical services team have curated a 2D/3D RAS panel of ~200 cancer cell lines that reflect the disease-relevant distribution of KRAS, NRAS, and HRAS alterations across major cancer types.
In this poster, our preclinical services team demonstrate how the platform can be used for the comprehensive interrogation of RAS pathway-targeting agents and to characterize selectivity profiles and mechanistic engagement of mutant-allele selective KRAS inhibitors.
Download to get the full details and to delve into the data.
For research use only. Not for use in diagnostic procedures.
Download Resource
Comprehensive 2D/3D RAS cell panel for mutation-specific inhibitor profiling: from screening to mechanistic validation